The GLP-1 safety check now includes where the medicine came from

A medicine can arrive looking convincing and still leave the most important questions unanswered. Who prescribed it? Who dispensed it? Was it made, stored and transported under the controls that apply in that country? If something goes wrong, is there a clinician and a regulator to report it to?

Those questions sit behind a new World Health Organization statement on GLP-1 receptor agonists, the medicines now widely discussed for diabetes and weight management. The statement is not a verdict against the drug class. WHO's two safety advisory committees said GLP-1 medicines have a well-established positive benefit-risk profile when they are used for approved indications and supervised by qualified health professionals.

The committees' concern is a different route: people obtaining products outside approved indications and medical settings, including through informal online channels. In that route, identity, quality, purity and strength may not be assured. Clinical screening, follow-up and adverse-event reporting may also be missing. The safety question therefore starts before a pen or vial is used.

That distinction matters because three ideas are easily collapsed into one. An approved medicine is not the same thing as every product that claims to contain its active ingredient. A legitimate prescription is not the same thing as a social-media recommendation. And a regulated pharmacy website is not the same thing as any page with a checkout button.

WHO's underlying position remains cautious rather than contradictory. Its 2025 obesity guideline made a conditional recommendation that GLP-1 therapies may be used for long-term treatment of adults living with obesity, excluding pregnant women from the guideline's scope. WHO called the recommendation conditional because questions remain about long-term use, stopping treatment, cost, health-system readiness and equity. Its July 2026 safety statement adds that authorised supply and professional supervision are part of the context in which the known benefit-risk profile applies.

The United States Food and Drug Administration makes a parallel but jurisdiction-specific distinction. Its current safety page says unapproved GLP-1 versions do not undergo the FDA's pre-market review for safety, effectiveness and quality. It also warns about fraudulent labels, products falsely sold for research use, dosing errors and injectable medicines arriving without adequate refrigeration.

This does not make "compounded" a synonym for "counterfeit". The FDA says a compounded medicine can be appropriate when a patient's medical need cannot be met by an approved product, but compounded medicines are not FDA-approved. Other countries use different legal categories and pharmacy systems. A rule written for the United States should not be silently treated as a global test.

The reporting numbers need the same restraint. As of 31 May 2026, the FDA said it had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency also says a report does not always establish that the product caused the event, and some parts of the compounding system are not required to submit reports. The figures are safety signals for investigation, not a count of proven injuries and not a direct comparison with approved products.

Earlier regulator cases show why the supply chain is more than packaging. In 2023, the European Medicines Agency reported falsified pens identified at wholesalers in the European Union and the United Kingdom. The packs carried features copied from genuine products, but the serial numbers showed as inactive when scanned in the European verification system. EMA said at the time that there was no evidence the affected pens had been dispensed by legal pharmacies. The lesson was not that every pen was suspect. It was that traceability controls caught a specific problem before appearance alone could settle it.

The UK's Medicines and Healthcare products Regulatory Agency also warned in 2023 that potentially fake pens had been obtained through non-legitimate routes, meaning routes that did not require a prescription from a qualified prescriber. Its public advice centred on legitimate prescribing and registered pharmacies. The details are UK-specific, but the broader boundary matches WHO's current statement: a medicine's route supplies evidence that the object itself cannot.

For readers, a source check is not a tool for self-diagnosis or judging a product by colour, cap shape or packaging photographs. Counterfeiters can copy visual details, and authorised products differ between markets. The useful questions are procedural. Is the prescriber qualified under local rules? Is the dispensing pharmacy or supplier registered with the relevant national authority? Is the product approved or otherwise lawfully supplied for the stated use in that jurisdiction? Does the service provide clinical screening and a route for follow-up? For an injectable product that requires temperature control, were the manufacturer's storage conditions maintained?

A suspicious bargain, a seller who avoids a prescription, or a parcel with unclear provenance is not something an image search can authenticate. National medicines regulators and pharmacy registers are the appropriate reference points, and concerns about side effects or product quality can be reported through the relevant national pharmacovigilance system. People who already have questions about a prescribed medicine should speak to their prescriber or pharmacist rather than changing or stopping it on the basis of a general news article.

The GLP-1 story is often presented as a contest between enthusiasm and alarm. WHO's latest statement is more exact. These medicines can have established benefits in approved, supervised use, while an unknown supply route introduces a separate layer of uncertainty. The pen is only the final object in a much longer safety chain.